In 2018, the FDA approved the combination of encorafenib and binimetinib (an anti-MEK1/2 protein kinase inhibitor) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The gene discussed is MAP2K1; the disease is metastatic melanoma.